Doxribtimine
CAS 50-89-5
Doxribtimine (CAS 50-89-5) is a Phase 2 pharmaceutical compound with 6 bioactivity targets and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | Ki | 22472.727272727272 nM | 11 | - |
| - | EC50 | 19985 nM | 8 | - |
| - | IC50 | 5210.591111111111 nM | 7 | - |
| - | Potency | 13509.05 nM | 2 | - |
| - | Kd | 10000000 nM | 1 | - |
| - | Ki | 0.09 | 1 | - |
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| THYMIDINE | 1372538 | SU | MTHSPL |
| DOXRIBTIMINE | 1372538 | SU | MTHSPL |
| thymidine | 1372538 | IN | RXNORM |
| doxribtimine | 1372538 | SY | RXNORM |
Side Effects
SIDER side-effect terms mapped to the drug or same-CAS compound identity.
| Side Effect | Drug Name | MedDRA Type | Concept ID |
|---|---|---|---|
| Abdominal discomfort | thymidine | LLT | C0232487 |
| Abdominal discomfort | thymidine | PT | C0232487 |
| Abdominal distension | thymidine | LLT | C0000731 |
| Abdominal distension | thymidine | PT | C0000731 |
| Abdominal pain | thymidine | LLT | C0000737 |
| Abdominal pain | thymidine | PT | C0000737 |
| Abdominal pain lower | thymidine | LLT | C0232495 |
| Abdominal pain lower | thymidine | PT | C0232495 |
| Abdominal pain upper | thymidine | LLT | C0232492 |
| Abdominal pain upper | thymidine | PT | C0232492 |
| Abdominal pain upper | thymidine | PT | C0232492 |
| Alanine aminotransferase increased | thymidine | LLT | C0151905 |
| Alanine aminotransferase increased | thymidine | PT | C0151905 |
| Amylase increased | thymidine | PT | C0151479 |
| Arthralgia | thymidine | LLT | C0003862 |
| Arthralgia | thymidine | PT | C0003862 |
| Aspartate aminotransferase increased | thymidine | LLT | C0151904 |
| Aspartate aminotransferase increased | thymidine | PT | C0151904 |
| Asthenia | thymidine | PT | C0004093 |
| Back pain | thymidine | LLT | C0004604 |
| Back pain | thymidine | PT | C0004604 |
| Blood amylase increased | thymidine | LLT | C0852913 |
| Blood creatine phosphokinase increased | thymidine | PT | C0853034 |
| Blood creatine phosphokinase increased | thymidine | LLT | C0853034 |
| Blood creatine phosphokinase increased | thymidine | PT | C0853034 |
| Body temperature increased | thymidine | LLT | C0015967 |
| Body temperature increased | thymidine | PT | C0015967 |
| Chest discomfort | thymidine | LLT | C0235710 |
| Chest discomfort | thymidine | PT | C0235710 |
| Chest pain | thymidine | LLT | C0008031 |
| Chest pain | thymidine | PT | C0008031 |
| Chest pain | thymidine | PT | C0008031 |
| Chest wall pain | thymidine | LLT | C0008035 |
| Connective tissue disorder | thymidine | LLT | C0009782 |
| Connective tissue disorder | thymidine | PT | C0009782 |
| Cough | thymidine | LLT | C0010200 |
| Cough | thymidine | PT | C0010200 |
| Cramp muscle | thymidine | LLT | C0026821 |
| Creatine phosphokinase increased | thymidine | LLT | C0151576 |
| Dermatitis | thymidine | PT | C0011603 |
| Diarrhoea | thymidine | LLT | C0011991 |
| Diarrhoea | thymidine | PT | C0011991 |
| Diarrhoea | thymidine | PT | C0011991 |
| Discomfort | thymidine | PT | C0234215 |
| Discomfort | thymidine | LLT | C0234215 |
| Discomfort | thymidine | PT | C0234215 |
| Disease progression | thymidine | LLT | C0242656 |
| Disease progression | thymidine | PT | C0242656 |
| Dizziness | thymidine | LLT | C0012833 |
| Dizziness | thymidine | PT | C0012833 |
| Dysgeusia | thymidine | LLT | C0013378 |
| Dysgeusia | thymidine | PT | C0013378 |
| Dyspepsia | thymidine | LLT | C0013395 |
| Dyspepsia | thymidine | PT | C0013395 |
| Fatigue | thymidine | LLT | C0015672 |
| Fatigue | thymidine | PT | C0015672 |
| Feeling abnormal | thymidine | PT | C1443060 |
| Fibromyalgia | thymidine | LLT | C0016053 |
| Fibromyalgia | thymidine | PT | C0016053 |
| Flank pain | thymidine | LLT | C0016199 |
| Flank pain | thymidine | PT | C0016199 |
| Frequent bowel movements | thymidine | LLT | C0239978 |
| Frequent bowel movements | thymidine | PT | C0239978 |
| Gastritis | thymidine | LLT | C0017152 |
| Gastritis | thymidine | PT | C0017152 |
| Gastrointestinal disorder | thymidine | LLT | C0017178 |
| Gastrointestinal disorder | thymidine | PT | C0017178 |
| Gastrointestinal pain | thymidine | PT | C0687713 |
| Gastrointestinal pain | thymidine | LLT | C0687713 |
| Gastrointestinal pain | thymidine | PT | C0687713 |
| Headache | thymidine | LLT | C0018681 |
| Headache | thymidine | PT | C0018681 |
| Hepatic pain | thymidine | LLT | C0522067 |
| Hepatic pain | thymidine | PT | C0522067 |
| Hepatitis | thymidine | LLT | C0019158 |
| Hepatitis | thymidine | PT | C0019158 |
| Hepatitis B | thymidine | LLT | C0019163 |
| Hepatitis B | thymidine | PT | C0019163 |
| Hepatitis acute | thymidine | LLT | C0267797 |
| Hepatitis acute | thymidine | PT | C0267797 |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Doxribtimine used for in pharmaceutical contexts?
Doxribtimine (CAS 50-89-5) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Doxribtimine?
Doxribtimine has SIDER side-effect terms including Abdominal discomfort, Abdominal distension, Abdominal pain, Abdominal pain lower, Abdominal pain upper; no DrugCentral/FAERS adverse-event association rows are rendered for this page. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Doxribtimine also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Thymidine with EU status "permitted".
What clinical phase is Doxribtimine in?
Doxribtimine is rendered with ChEMBL max phase 2.